# HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04564872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04564872](<https://clinicaltrials.gov/study/NCT04564872>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04564872

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

## Technical summary

Registry record NCT04564872. Randomized; double masking; primary purpose treatment. Start 2020-11-13 (actual); primary completion 2022-01-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 465 participants (enrolled count; ClinicalTrials.gov record NCT04564872, source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)
- Started: 2020-11-13 (actual) (ClinicalTrials.gov record NCT04564872, source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)
- Primary completion: 2022-01-21 (actual) (ClinicalTrials.gov record NCT04564872, source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)
- Completion: 2022-08-29 (actual) (ClinicalTrials.gov record NCT04564872, source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04564872, source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04564872-2022-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): HSK7653 10 mg Q2W
- Intervention (Drug): HSK7653 25 mg Q2W
- Intervention (Drug): Linagliptin 5 mg QD
- Lead sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 14407090d7ab836ca4185ecb9f343ef5ee346fe7cf022920182d645c96f18b79
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
